Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$40.62 0.0%	$36.66	$26.20 ▼ $63.50	$1.82B	1.7	523,208 shs	444,797 shs
BHC Bausch Health Companies	$4.68 +1.6%	$5.55	$3.96 ▼ $9.85	$1.69B	0.34	2.61 million shs	1.15 million shs
GLPG Galapagos	$27.75 +3.3%	$25.46	$22.36 ▼ $31.23	$1.83B	0.02	234,021 shs	421,366 shs
ZVRA Zevra Therapeutics	$8.66 +2.7%	$7.54	$4.20 ▼ $9.76	$473.52M	1.87	637,468 shs	1.47 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+8.93%	+22.68%	+11.17%	-23.79%
BHC Bausch Health Companies	0.00%	+2.75%	-8.78%	-24.01%	-33.97%
GLPG Galapagos	0.00%	+9.60%	+12.53%	+9.08%	-4.57%
ZVRA Zevra Therapeutics	0.00%	+10.04%	+21.12%	+7.31%	+79.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	2.1748 of 5 stars	3.5	0.0	0.0	2.9	4.2	0.0
BHC Bausch Health Companies	4.1948 of 5 stars	2.9	2.0	4.0	3.2	1.7	1.9
GLPG Galapagos	0.4527 of 5 stars	0.8	3.0	0.0	2.7	0.0	0.6
ZVRA Zevra Therapeutics	2.7603 of 5 stars	4.6	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$94.60	132.89% Upside
BHC Bausch Health Companies	1.86	Reduce	$7.42	58.65% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-8.71% Downside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	157.34% Upside

Current Analyst Ratings Breakdown

Latest ZVRA, APGE, GLPG, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/2/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00
4/7/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform	$9.00 ➝ $8.50
3/13/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$95.00
3/13/2025	ZVRA Zevra Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
3/13/2025	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/13/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/12/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$18.00
3/12/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/12/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$7.50 per share	N/A
BHC Bausch Health Companies	$9.73B	0.17	$4.97 per share	0.94	($0.89) per share	-5.25
GLPG Galapagos	$288.19M	6.35	N/A	N/A	$47.57 per share	0.58
ZVRA Zevra Therapeutics	$23.61M	20.05	N/A	N/A	$1.71 per share	5.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$83.99M	-$3.29	N/A	N/A	N/A	N/A	-21.81%	-20.94%	N/A
BHC Bausch Health Companies	-$46M	-$0.11	N/A	1.00	0.37	-0.48%	-577.82%	5.24%	7/30/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
ZVRA Zevra Therapeutics	-$46.05M	-$1.90	N/A	43.30	N/A	-342.63%	-159.54%	-51.50%	N/A

Latest ZVRA, APGE, GLPG, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million
3/11/2025	Q4 2024	ZVRA Zevra Therapeutics	-$0.39	-$0.67	-$0.28	-$0.67	$8.93 million	$12.00 million
3/3/2025	Q4 2024	APGE Apogee Therapeutics	-$0.94	-$1.19	-$0.25	-$1.19	N/A	N/A
2/19/2025	Q4 2024	BHC Bausch Health Companies	$1.65	$1.21	-$0.44	$0.25	$2.51 billion	$2.56 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Companies	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.39	16.39
BHC Bausch Health Companies	N/A	0.86	0.62
GLPG Galapagos	N/A	9.97	9.81
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BHC Bausch Health Companies	78.65%
GLPG Galapagos	32.46%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	36.10%
BHC Bausch Health Companies	8.05%
GLPG Galapagos	2.91%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	44.88 million	28.77 million	Optionable
BHC Bausch Health Companies	19,900	362.40 million	338.06 million	Optionable
GLPG Galapagos	1,310	65.90 million	63.98 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

ZVRA, APGE, GLPG, and BHC Headlines

Recent News About These Companies

Zevra Therapeutics' (ZVRA) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

May 17 at 2:18 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16 at 11:45 AM | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15 at 8:58 PM | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 14, 2025 | taiwannews.com.tw

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Wednesday

May 9, 2025 | marketbeat.com

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025 | globenewswire.com

Barclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 3, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Brokerages

May 3, 2025 | marketbeat.com

85,818 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by Boothbay Fund Management LLC

May 2, 2025 | marketbeat.com

Zevra Therapeutics to Participate in the Citizens Life Science Conference

May 1, 2025 | finance.yahoo.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Nantahala Capital Management LLC

April 30, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

April 28, 2025 | marketbeat.com

Geode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

April 26, 2025 | marketbeat.com

Diadema Partners LP Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

April 24, 2025 | marketbeat.com

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

April 21, 2025 | finance.yahoo.com

Zevra Therapeutics urges stockholders to vote for director nominees

April 21, 2025 | markets.businessinsider.com

Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns

April 21, 2025 | quiverquant.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Position Boosted by Altium Capital Management LLC

April 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA, APGE, GLPG, and BHC Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$40.62 -0.02 (-0.05%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$40.62 0.00 (0.00%)

As of 05/16/2025 05:06 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Bausch Health Companies NYSE:BHC

$4.68 +0.08 (+1.63%)

Closing price 05/16/2025 03:59 PM Eastern

Extended Trading

$4.57 -0.11 (-2.35%)

As of 05/16/2025 07:42 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Galapagos NASDAQ:GLPG

$27.75 +0.89 (+3.31%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$27.65 -0.10 (-0.37%)

As of 05/16/2025 07:51 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Zevra Therapeutics NASDAQ:ZVRA

$8.66 +0.23 (+2.73%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$8.53 -0.13 (-1.50%)

As of 05/16/2025 07:19 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time